ENTASIS THERAPEUTICS

entasis-therapeutics-logo

Entasis Therapeutics is developing a portfolio of innovative cures for serious drug-resistant bacterial infections, a global health crisis affecting the lives of millions of patients. Entasisโ€™ anti-infective discovery platform has produced a pipeline of meaningfully differentiated programs which target serious bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), and zoliflodacin (targeting Neisseria gonorrhoeae).

#SimilarOrganizations #People #Financial #Website #More

ENTASIS THERAPEUTICS

Social Links:

Industry:
Biotechnology Health Care Medical Pharmaceutical

Founded:
2015-01-01

Address:
Waltham, Massachusetts, United States

Country:
United States

Website Url:
http://www.entasistx.com

Total Employee:
11+

Status:
Active

Contact:
(781)810-0120

Email Addresses:
[email protected]

Total Funding:
199.5 M USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager Google Universal Analytics Font Awesome


Similar Organizations

apellis-pharmaceuticals-logo

Apellis Pharmaceuticals

Apellis Pharmaceuticals focusesย on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.

arrakis-therapeutics-logo

Arrakis Therapeutics

Arrakis Therapeutics is a biopharmaceutical developing drugs for neurological disorders and other diseases.

celsius-therapeutics-logo

Celsius Therapeutics

Celsius Therapeutics is a biotechnology company that develops precision medicines for cancer and autoimmune disease patients.

centerline-biomedical-logo

Centerline Biomedical

Centerline Biomedical, a Cleveland Clinic spin-off, is developing an innovative system

cortexyme-logo

Cortexyme

Cortexyme is developing treatments for Alzheimer's and other degenerative disorders.

dyne-therapeutics-logo

Dyne Therapeutics

Dyne Therapeutics is a developer of targeted therapies intended for serious muscle diseases.

editas-medicine-logo

Editas Medicine

Editas Medicine is engaged in discovering and developing a novel class of genome editing therapeutics.

elicio-therapeutics-logo

Elicio Therapeutics

Elicio Therapeutics develops an immuno-tumor vaccine to treat cancer.

enlibrium-logo

Enlibrium

Enlibrium is a developing novel drugs

imtherapeutics-logo

IMTherapeutics

IM Therapeutics develops personalized immuno-therapeutic drugs.

phyla-logo

Phyla

Phyla is developing alternative therapies for antibiotics.

tiburio-therapeutics-logo

Tiburio Therapeutics

Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.

vico-therapeutics-logo

Vico Therapeutics

Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies.


Current Advisors List

greg-norden_image

Greg Norden Board Member @ Entasis Therapeutics
Board_member
2016-10-01

david-hastings_image

David Hastings Board Member @ Entasis Therapeutics
Board_member
2018-04-01

heather-behanna_image

Heather Behanna Board Member @ Entasis Therapeutics
Board_member
2017-09-01

tracy-saxton_image

Tracy Saxton Board Member @ Entasis Therapeutics
Board_member

andy-staples_image

Andy Staples Board Member @ Entasis Therapeutics
Board_member
2015-05-01

david-meek_image

David Meek Chairman Of The Board @ Entasis Therapeutics
Board_member
2019-06-01

nicholas-galakatos_image

Nicholas Galakatos Board Chairman @ Entasis Therapeutics
Board_member
2016-03-01

manos-perros_image

Manos Perros Board Member @ Entasis Therapeutics
Board_member

Current Employees Featured

michael-gutch_image

Michael Gutch
Michael Gutch Chief Medical Officer @ Entasis Therapeutics
Chief Medical Officer

david-meek_image

David Meek
David Meek Chief Executive Officer @ Entasis Therapeutics
Chief Executive Officer
2021-09-01

john-mueller_image

John Mueller
John Mueller Chief Development Officer @ Entasis Therapeutics
Chief Development Officer
2016-07-01

john-mueller_image

John Mueller
John Mueller Vice President, Program Management & Early Development @ Entasis Therapeutics
Vice President, Program Management & Early Development
2015-05-01

matthew-ronsheim_image

Matthew Ronsheim
Matthew Ronsheim Chief Pharmaceutical Sciences & Manufacturing Officer @ Entasis Therapeutics
Chief Pharmaceutical Sciences & Manufacturing Officer

manos-perros_image

Manos Perros
Manos Perros Chief Executive Officer @ Entasis Therapeutics
Chief Executive Officer
2015-05-01

ruben-tommasi_image

Ruben Tommasi
Ruben Tommasi CSO @ Entasis Therapeutics
CSO

Founder


john-mueller_image

John Mueller

Stock Details


Company's stock symbol is NASDAQ:ETTX

Investors List

carb-x_image

CARB-X

CARB-X investment in Grant - Entasis Therapeutics

pivotal-bioventure-partners_image

Pivotal bioVenture Partners

Pivotal bioVenture Partners investment in Series B - Entasis Therapeutics

sofinnova-ventures_image

Sofinnova Investments

Sofinnova Investments investment in Series B - Entasis Therapeutics

texas-pacific-group_image

TPG

TPG investment in Series B - Entasis Therapeutics

carb-x_image

CARB-X

CARB-X investment in Grant - Entasis Therapeutics

eventide-asset-management_image

Eventide

Eventide investment in Series B - Entasis Therapeutics

clarus-ventures_image

Clarus Ventures

Clarus Ventures investment in Series B - Entasis Therapeutics

frazier-healthcare-ventures_image

Frazier Healthcare Partners

Frazier Healthcare Partners investment in Series B - Entasis Therapeutics

novo-a-s_image

Novo Holdings

Novo Holdings investment in Series B - Entasis Therapeutics

Official Site Inspections

http://www.entasistx.com Semrush global rank: 4.54 M Semrush visits lastest month: 2.31 K

  • Host name: aec037177372cc6cd.awsglobalaccelerator.com
  • IP address: 15.197.225.128
  • Location: United States
  • Latitude: 37.751
  • Longitude: -97.822
  • Timezone: America/Chicago

Loading ...

More informations about "Entasis Therapeutics"

Entasis Therapeutics - Crunchbase Company Profile

Contact Email [email protected] Phone Number (781)810-0120 Entasis Therapeutics is developing a portfolio of innovative cures for serious drug-resistant bacterial infections, a global health crisis affecting the lives of millions โ€ฆSee details»

Entasis Therapeutics Information - RocketReach

Entasis Therapeutics, a subsidiary of Innoviva, Inc., is developing a portfolio of innovative cures for serious drug-resistant bacterial infections, a global health crisis affecting the lives of โ€ฆSee details»

Entasis Therapeutics - Devex

Focused on next generation antibacterial therapeutics. Our Story Entasis Therapeutics was established in 2015 as a spin-out from and with initial funding from AstraZeneca, and all rights โ€ฆSee details»

Entasis Therapeutics - LinkedIn

Entasis Therapeutics, a subsidiary of Innoviva, Inc., is developing a portfolio of innovative cures for serious drug-resistant bacterial infections, a global health crisis affecting the lives of ...See details»

Entasis Therapeutics Holdings Inc. - AnnualReports.com

Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat โ€ฆSee details»

Entasis Therapeutics - Company Profile & Staff Directory

Entasis Therapeutics, a subsidiary of Innoviva, Inc., is developing a portfolio of innovative cures for serious drug-resistant bacterial infections, a global health crisis affecting the lives of โ€ฆSee details»

Entasis Therapeutics, Inc. - Drug pipelines, Patents ... - Patsnap

Www.entasistx.com. Subsidiary Company | 2015 | Massachusetts, United States | 50-100 | NASDAQ: ETTX | www.entasistx.com. Last update 01 Nov 2024. Overview. Pipeline. Deal. ...See details»

Entasis Therapeutics - Company Profile - Tracxn

Dec 15, 2024 Developer of a portfolio of cures for serious drug-resistant bacterial infections. The company is developing small molecules to treat serious multidrug-resistant Gram-negative โ€ฆSee details»

Entasis Therapeutics - Craft

Jul 11, 2022 Entasis Therapeutics has 3 employees at their 1 location and $7 m in annual revenue in FY 2019. See insights on Entasis Therapeutics including office locations, โ€ฆSee details»

Entasis Therapeutics - Overview, News & Similar companies

Jul 11, 2022 Entasis Therapeutics contact info: Phone number: (781) 810-0120 Website: www.entasistx.com What does Entasis Therapeutics do? Entasis is a late-stage clinical โ€ฆSee details»

Entasis Therapeutics Company Profile -Sales, Contacts, โ€ฆ

Entasis Therapeutics is in the Biotechnical Research, Commercial industry within the Engineering, Accounting, Research, and Management Services sector and has been in business for โ€ฆSee details»

Entasis Therapeutics Management Team | Org Chart

Entasistx.com; comcast.net; 4 860434XXXX; 781228XXXX; 781810XXXX; 860304XXXX; View Similar People. Related Companies VFP Pharmacy Group. 75 $13m connectRN. 662 $44m โ€ฆSee details»

Entasis - VentureRadar

Entasis' anti-infective discovery platform has produced a pipeline of meaningfully differentiated programs which target serious bacterial infections, including ETX2514SUL (targeting โ€ฆSee details»

Entasis Therapeutics Holdings Inc. in Waltham, MA - (781) 810-0120

Entasis Therapeutics Holdings Inc. is in the Pharmaceutical Preparations business. View competitors, revenue, employees, website and phone number.See details»

Entasis Therapeutics Holdings Overview | Salary.com

Discover essential details about Entasis Therapeutics Holdings, including address, contact, and journey of our company's evolution.See details»

Entasis Therapeutics Completes Initial Closing of $20M Private ...

May 3, 2021 Company ContactKyle Dow Entasis Therapeutics (781) 810-0114 [email protected] Investor Relations ContactsJames SaliernoThe Ruth Group(646) โ€ฆSee details»

Entasis Therapeutics to Participate in the Cantor Fitzgerald Virtual ...

For more information, visit www.entasistx.com. Entasis Contacts Company: Kyle Dow Entasis Therapeutics (781) 810-0114 [email protected] Investor Relations: Bruce Mackle โ€ฆSee details»

Entasis Therapeutics, a Wholly Owned Subsidiary of Innoviva, โ€ฆ

Oct 19, 2022 Entasis Therapeutics Holdings Inc.--- Presentations Reinforce Topline Safety and Efficacy Findings and Highlight Consistency between Clinical and Microbiological EndpointsSee details»

Entasis Therapeutics Introduces ETX0462, a First-in-Class โ€ฆ

WALTHAM, Mass., July 01, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and โ€ฆSee details»

ETX-0462 - Drug Targets, Indications, Patents - Synapse

Originator Organization. Entasis Therapeutics Holdings, Inc. Active Organization. Combating Antibiotic Resistant Bacteria Accelerator Entasis ... [email protected] Media โ€ฆSee details»

linkstock.net © 2022. All rights reserved